Coherus Oncology (CHRS) Receivables (2013 - 2026)
Coherus Oncology (CHRS) posted Receivables of $22.5 million for Q1 2026, up 22.22% sequentially from $18.4 million in Q4 2025, and down 63.95% YoY from $62.4 million in Q1 2025.
Coherus Oncology (CHRS) Receivables (2013 - 2026) Analysis & Trends
Coherus Oncology has reported Receivables for 13 years, with the latest figure at $22.5 million in Q1 2026.
- Quarterly Receivables fell 63.95% year-over-year to $22.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $22.5 million (down 63.95% YoY) and the FY2025 annual result came in at $18.4 million, down 84.94% from the prior year.
- Receivables climbed to $22.5 million in Q1 2026 per CHRS's latest filing, from $18.4 million in the prior quarter.
- Over five years, Receivables peaked at $313.6 million in Q2 2024 and troughed at $18.4 million in Q4 2025.
- A 5-year average of $149.8 million and a median of $119.6 million in 2025 frame the typical range for Receivables.
- The sharpest annual moves came in 2024 and 2025: Receivables soared 180.06% in 2024, then sank 84.94% in 2025.
- Over 5 years, Receivables stood at $110.0 million in 2022, then surged by 136.92% to $260.5 million in 2023, then tumbled by 53.04% to $122.3 million in 2024, then tumbled by 84.94% to $18.4 million in 2025, then climbed by 22.22% to $22.5 million in 2026.
- According to Business Quant data, Receivables over the past three periods registered $22.5 million, $18.4 million, and $250.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 2.13 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 6.57 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.93 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 160.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 1.06 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 912.74 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 215.33 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 1.09 Bn |
| 10 | Coherus Oncology | 203.82 Mn | 98.51 Mn | 10.07 Mn | 14.25 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 14.25 Mn |
| Mar 31, 2026 | 22.51 Mn |
| Dec 31, 2025 | 18.42 Mn |
| Sep 30, 2025 | 250.50 Mn |
| Jun 30, 2025 | 119.64 Mn |
| Mar 31, 2025 | 62.44 Mn |
| Dec 31, 2024 | 122.33 Mn |
| Sep 30, 2024 | 198.80 Mn |
| Jun 30, 2024 | 313.57 Mn |
| Mar 31, 2024 | 284.15 Mn |
| Dec 31, 2023 | 260.52 Mn |
| Sep 30, 2023 | 216.51 Mn |
| Jun 30, 2023 | 141.31 Mn |
| Mar 31, 2023 | 101.46 Mn |
| Dec 31, 2022 | 109.96 Mn |
| Sep 30, 2022 | 91.19 Mn |
| Jun 30, 2022 | 115.71 Mn |
| Mar 31, 2022 | 117.04 Mn |
| Dec 31, 2021 | 123.02 Mn |
| Sep 30, 2021 | 136.35 Mn |